What Adimab does

Adimab is a privately held therapeutic antibody discovery and engineering company founded in 2007 and headquartered in Lebanon, New Hampshire, with a secondary office in Mountain View, California. The company operates a proprietary yeast-based antibody discovery platform that delivers fully human IgGs, HCAbs (heavy chain-only antibodies), multispecifics, and TCRs by combining synthetic and immune libraries with integrated engineering and developability assessment. Its technology suite includes Chain Exchange (ChEx) for high-throughput bispecific generation, orthogonal CH1:Cκ interface designs for correct heavy/light chain pairing, a TCR-targeting VHH platform, structure-based CD3 engineering to decouple CD3 affinity from polyreactivity, ML-designed synthetic HCAb libraries, and an internal Atlas database linking 15+ years of experimental data across 1,431 programs and 2.85 million clones for ML-driven developability prediction.

The company runs a partnership-only, no-internal-pipeline business model serving pharmaceutical and biotechnology companies of all sizes across three engagement structures: Funded Discovery, where Adimab scientists execute programs on partners' behalf and deliver leads within roughly four months; Platform Transfer, where partner labs (GSK, Biogen, Novo Nordisk, Merck, Lilly, Takeda) internalize the yeast-based platform; and Non-Exclusive Programs, which license modular components such as CD3/CD28 binders and heterodimerization mutation sets to 20-25+ partners. Revenue is generated through research funding, upfront license fees, milestone payments, and royalties on programs that reach development and commercialization.

Adimab reports more than 140 biopharma partnerships, 675+ therapeutic programs, 90+ clinical-stage assets, and 6 commercial product approvals since inception (GSK's Exdensur/depemokimab, Innovent's TYVYT and SINTBILO, IASO Bio's FUCASO, Invivyd's PEMGARDA, Sun Pharma's UNLOXCYT). In 2024, the company established the Adimab Royalty Company (ARC) to house royalty rights from approximately 500 completed programs, creating a structure for shareholders to participate in either the operating company or the royalty portfolio. Adimab is led by Co-Founder and Executive Chairman Tillman U. Gerngross, PhD, CEO Philip Chase, President and CSO Eric Krauland, PhD, and CFO Ryan McGovern, with board representation from Polaris Partners, SV Health Investors, and Mithril Capital Management.

Name

Adimab

Legal name

Adimab, LLC

Website

http://www.adimab.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

101–250 employees

Short description

Adimab is a private, partnership-based therapeutic antibody discovery and engineering company using a proprietary yeast-based platform to deliver IgGs, HCAbs, multispecifics, and TCRs for pharmaceutical and biotechnology partners, with 140+ partnerships and 6 commercial product approvals since 2007.

Ownership category

akta.pro rank

Product category

Therapeutic Antibody Discovery Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

Keywords

• Antibody discovery platform
• Therapeutic antibody engineering
• Yeast display libraries
• Bispecific antibody development
• Biologics discovery services

Headquarters

HQ city

Lebanon

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Funded Discovery Partnerships: Partners pay for antibody discovery and engineering services where Adimab scientists drive programs on partners' behalf. Revenue generated through research funding, milestone payments, and technology access fees. Within four months of project initiation, Adimab delivers high-quality leads and detailed data packages.
2. Platform Transfer Licensing: Transfer of proprietary yeast-based discovery platform to pharmaceutical partners for in-house operation. Partners receive training, ongoing support, and platform updates. GSK was the first Platform Transfer collaborator and internalized the technology for depemokimab development. Other collaborators include Biogen, Lilly, Merck, Novo Nordisk, and Takeda.
3. Non-Exclusive Program Licensing: Modular access to validated discovery and engineering modules (CD3/CD28 binders, heterodimerization solutions) without full platform integration. Partners pay for access to specific validated components. More than 25 partners have licensed CD3/CD28 technologies non-exclusively.
4. Milestone and Royalty Payments: Partners exercise commercial options and pay milestones as programs advance through development. In 2025, 10 partners exercised commercial options. Adimab has created the Adimab Royalty Company (ARC) to manage royalty rights from nearly 500 completed therapeutic programs. Partners have exercised more than 125 commercial licenses to option rights to advance programs into clinical development.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels6 records

Core offering

Adimab operates a proprietary yeast-based antibody discovery and engineering platform that delivers therapeutic IgGs, HCAbs, multispecifics, TCRs, and T cell engagers to pharmaceutical and biotechnology partners. Services are delivered through three partnership models: Funded Discovery (Adimab scientists run partner-funded programs), Platform Transfer (licensing of the proprietary platform for in-house partner operation), and Non-Exclusive Programs (modular access to validated components such as CD3/CD28 binders and heterodimerization solutions).

Product overview

Adimab offers a unified therapeutic antibody discovery and engineering platform consisting of proprietary yeast-based technologies for antibody discovery, engineering, and multispecific construction. The core platform delivers IgGs, HCAbs, and multispecifics with emphasis on developability. Key products include the Antibody Discovery Platform (synthetic and immune yeast libraries), Antibody Engineering services, Multispecific Antibodies and T Cell Engagers (with proprietary CD3/CD28 binders and ChEx technology), and the Protein/TCR Engineering Platform. Modular add-ons include the TCE Toolkit (non-exclusive CD3/CD28 antibodies), Heterodimerization Solutions (orthogonal CH1:Cκ and CH3 mutations), and the Atlas Database (ML-powered data integration with 1,431 programs). Services are delivered through Funded Discovery (partner-funded discovery programs), Platform Transfer (in-house platform enablement), and Non-Exclusive Programs (plug-and-play modules). Six commercial products have been approved including GSK's Exdensur (depemokimab), Innovent's TYVYT and SINTBILO, IASO Bio's FUCASO, Invivyd's PEMGARDA, and Sun Pharma's UNLOXCYT.

Differentiator

Problem solved

Functional benefit

Products and services

• Antibody Discovery Platform Proprietary yeast-based antibody discovery platform combining fully human synthetic and immune libraries to deliver therapeutic IgGs, HCAbs, and multispecifics that are highly specific, stable, and developable. Delivered to pharmaceutical and biotech partners as part of Funded Discovery, Platform Transfer, and Non-Exclusive Programs.
• Antibody Engineering and Optimization Engineering services that transform antibody leads into high-affinity, highly developable candidates through guided engineering, ML-assisted developability prediction, and high-throughput screening. Used by partners across Funded Discovery and Platform Transfer engagements.
• Multispecific Antibodies and T Cell Engagers Bispecific and multispecific antibody engineering including proprietary solutions for Fc (HC:HC) and Fab (HC:LC) heterodimerization, the CD3/CD28 binder panel for T cell engagers, and Chain Exchange (ChEx) technology for high-throughput generation of correctly paired multispecifics. Delivered through Funded Discovery and Non-Exclusive Programs (CD3/CD28 components licensed non-exclusively to 25+ partners).
• Protein and TCR Engineering Platform Yeast-based protein engineering platform for therapeutic proteins and T cell receptors (TCRs). Includes dual-mode TCR-Fc expression, all-CDR diversification, deep mutational scanning, and AI-guided engineering for tailored binding, stability, and expression. Used for TCR-based therapeutics and other non-antibody protein scaffolds.
• Funded Discovery Partner-funded antibody discovery and optimization service in which Adimab scientists execute programs on the partner's behalf. Delivers panels of diverse IgG and/or HCAb proteins with full characterization data within approximately four months of project initiation, transferring leads to the partner for advancement to the clinic.
• Platform Transfer Structured technology licensing arrangement in which Adimab's proprietary yeast-based discovery platform is transferred to a partner's laboratory for in-house operation. Includes training, ongoing support, access to unique library diversities, and platform updates. Platform Transfer partners include GSK, Biogen, Novo Nordisk, Merck, Lilly, and Takeda, with partners having initiated 200+ internal programs.
• Non-Exclusive Programs Modular access to Adimab's validated discovery and engineering modules — including characterized CD3 and CD28 antibodies in IgG and VHH formats, and CH1:Ckappa/CH3 heterodimerization mutation sets — without full platform integration. Licensed non-exclusively; trusted by 20+ partners.

Quantifiable outcome

• 90 clinical programs initiated by partners
• +7 more outcomes

Named customers18 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature10 records

Partnerships

55 partnerships are on record, tiered flagship, core and minor.

• GSKflagshipStrategic or Co-development Partner · 15 April 2026GSK was Adimab's first Platform Transfer collaborator, internalizing Adimab's proprietary yeast-based technology for antibody discovery, optimization, production, and characterization. GSK used the platform for depemokimab development, achieving regulatory approvals in the EU, China, US, Japan, and UK. GSK continues to use the Adimab platform to support other internal programs. Depemokimab is the first approved product from Adimab's Platform Transfer model.
• BiogencoreStrategic or Co-development PartnerPlatform Transfer collaborator with Adimab technology transferred and implemented at their facility. Biogen has exercised commercial options including in 2025.
• Novo NordiskcoreStrategic or Co-development PartnerPlatform Transfer collaborator with Adimab technology transferred and implemented at their facility for internal antibody discovery programs.
• MerckcoreStrategic or Co-development PartnerPlatform Transfer collaborator with Adimab technology transferred and implemented at their facility for internal antibody discovery programs.
• LillycoreStrategic or Co-development PartnerPlatform Transfer collaborator with Adimab technology transferred and implemented at their facility. Also a funded discovery partner with expanded collaboration in 2025.
• TakedacoreStrategic or Co-development PartnerPlatform Transfer collaborator with Adimab technology transferred and implemented at their facility for internal antibody discovery programs.
• AlnylamcoreStrategic or Co-development PartnerFunded discovery partner with expanded collaboration in 2025. Partnership for therapeutic antibody discovery programs.
• Bristol Myers SquibbcoreStrategic or Co-development PartnerFunded discovery partner for therapeutic antibody discovery programs.
• InnoventcoreStrategic or Co-development PartnerFunded discovery partner. Two commercial products from partnership: TYVYT (sintilimab) approved in China for multiple cancers, and SINTBILO (tafolecimab) approved for hypercholesterolemia.
• NovartiscoreStrategic or Co-development PartnerFunded discovery partner with commercial options exercised in 2025.
• RegeneroncoreStrategic or Co-development PartnerFunded discovery partner with expanded collaboration in 2025.
• VertexcoreStrategic or Co-development PartnerFunded discovery partner for therapeutic antibody discovery programs.
• RoivantcoreStrategic or Co-development PartnerNew alliance established in 2025.
• Central TherapeuticsminorStrategic or Co-development PartnerNew alliance established in 2025.
• Enara BiominorStrategic or Co-development PartnerNew alliance established in 2025.
• DragonflycoreStrategic or Co-development PartnerEarly-stage venture-backed partner for antibody therapeutics development.
• NextPoint TherapeuticscoreStrategic or Co-development PartnerEarly-stage venture-backed partner with expanded collaboration and commercial options exercised.
• Santa Ana BiocoreStrategic or Co-development PartnerEarly-stage venture-backed partner with commercial options exercised in 2024 and 2025.
• Tizona TherapeuticscoreStrategic or Co-development PartnerPartnered for discovery and optimization of TTX-080, an HLA-G antibody that advanced into clinical trials for solid tumors.
• Kelonia TherapeuticscoreStrategic or Co-development PartnerEarly-stage venture-backed partner with new clinical programs in 2025.
• AlectorcoreStrategic or Co-development PartnerMid-size public biopharmaceutical company partner for antibody therapeutics development.
• Cullinan TherapeuticscoreStrategic or Co-development PartnerMid-size public biopharmaceutical company with expanded collaboration in 2025.
• Scholar RockcoreStrategic or Co-development PartnerMid-size public biopharmaceutical company partner for antibody therapeutics development.
• 3T BiosciencesminorStrategic or Co-development PartnerExpanded collaboration in 2025.
• CompugenminorStrategic or Co-development PartnerExpanded collaboration in 2025.
• RedRidgeminorStrategic or Co-development PartnerExpanded collaboration in 2025.
• Therini BiominorStrategic or Co-development PartnerExpanded collaboration in 2025.
• iTeoscoreStrategic or Co-development PartnerMid-size public biopharmaceutical company partner with new clinical programs in 2025.
• AbogencoreStrategic or Co-development PartnerPartner with new clinical programs in 2025.
• InvivydcoreStrategic or Co-development PartnerPartner with commercial product PEMGARDA (pemivibart) authorized for emergency use in the US for COVID-19 prophylaxis.
• Triveni BiocoreStrategic or Co-development PartnerPartner with new clinical programs in 2025, including commercial options exercised.
• WerewolfcoreStrategic or Co-development PartnerEarly-stage venture-backed partner with commercial options exercised.
• SixPeaks BiocoreStrategic or Co-development PartnerPartner with commercial options exercised in 2025.
• Montis BiosciencesminorStrategic or Co-development PartnerPartner with commercial options exercised in 2025.
• BambusaminorStrategic or Co-development PartnerPartner with commercial options exercised in 2025.
• IkaikaminorStrategic or Co-development PartnerPartner with commercial options exercised in 2025.
• Meiji Seika PharmaminorStrategic or Co-development PartnerPartner with commercial options exercised in 2025.
• REGiMMUNEminorStrategic or Co-development PartnerPartner with commercial options exercised in 2024.
• NextPoint TherapeuticscoreStrategic or Co-development PartnerPartner with commercial options exercised in 2024.
• Variant BiominorStrategic or Co-development PartnerNew alliance established in 2025.
• TriptychminorStrategic or Co-development PartnerNew alliance established in 2025.
• Onco3RminorStrategic or Co-development PartnerNew alliance established in 2025.
• BiotheuscoreStrategic or Co-development PartnerPartner advancing PM-1080, an EGFR × cMET bispecific antibody incorporating Adimab's CH1-Cκ heterodimerization technology, into Phase III trials for colorectal cancer and NSCLC.
• BioNTechcoreStrategic or Co-development PartnerPartner logo displayed on partnering page.
• Boehringer IngelheimcoreStrategic or Co-development PartnerPartner logo displayed on partnering page.
• Janssen PharmaceuticalscoreStrategic or Co-development PartnerPartner logo displayed on partnering page.
• Sun PharmacoreStrategic or Co-development PartnerPartner with commercial product UNLOXCYT (cosibelimab) approved in the US for cutaneous squamous cell carcinoma.
• IASO BiocoreStrategic or Co-development PartnerPartner with commercial product FUCASO (equecabtagene autoleucel) approved in China for multiple myeloma.
• iOmxminorStrategic or Co-development PartnerExpanded collaboration in 2024.
• Candid TherapeuticsminorStrategic or Co-development PartnerNew alliance established in 2024.
• Incendia TherapeuticsminorStrategic or Co-development PartnerNew alliance established in 2024.
• Leyden LabsminorStrategic or Co-development PartnerNew alliance established in 2024.
• Treeline BiosciencesminorStrategic or Co-development PartnerNew alliance established in 2024.
• Memorial Sloan Kettering Cancer CentercoreStrategic or Co-development PartnerAcademic medical center partner logo displayed on partnering page.
• MD Anderson Cancer CentercoreStrategic or Co-development PartnerAcademic medical center partner logo displayed on partnering page.

Scale indicators19 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• Atreca: Clinical-stage biotech using its immune repertoire capture technology for antibody discovery, with partnership and internal programs. Comparable discovery technology stack aimed at biopharma partners.
• Absci: AI-driven biologics discovery platform using generative AI and high-throughput wet lab to design antibodies. Emerging AI-first competitor to established platforms like Adimab in therapeutic antibody discovery partnerships.
• EvolutionaryScale: AI protein language model company developing foundation models for protein design including therapeutic applications. Adjacent emerging AI-native player competing for partner interest in computational antibody design.
• BigHat Biosciences: AI-native antibody design company combining ML with high-throughput wet-lab testing. Emerging AI-driven alternative that could compete with Adimab's yeast-based platform by offering faster in silico lead generation.

Direct peers

• Genmab: Danish antibody therapeutics company with proprietary platforms (DuoBody, HexaBody, etc.) enabling bispecific and next-gen antibody creation. Comparable in building partner-friendly antibody technologies and generating approved products (Darzalex, etc.) through platform-based deals.
• Specifica: Antibody discovery company providing in vitro display-based antibody libraries and engineering for therapeutic partners. Direct competitor focused on discovery services without internal pipeline, similar to Adimab's partnership-only model.
• AbCellera Biologics: Public antibody discovery platform using single-cell screening and proprietary technology for therapeutic antibody discovery and engineering. Directly competes with Adimab for biopharma partnership deals, offering an alternative discovery engine with similar partnership-based GTM.
• Harbour BioMed: Biopharma with proprietary H2L2 and HCAb transgenic mouse platforms plus antibody discovery/engineering services. Closely comparable to Adimab in offering antibody discovery partnerships across multiple therapeutic areas with heavy codeveloping/partnership focus.

Broad incumbents

• Charles River Laboratories: Large CRO with biologics discovery capabilities including antibody discovery through its CDMO and research services divisions. Broader incumbent offering Adimab-relevant services as part of a much larger CRO portfolio.
• WuXi Biologics: Global biologics CRO/CDMO offering antibody discovery, development, and manufacturing services. Broader portfolio incumbent competing with Adimab in antibody discovery services for global biopharma partners.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/adimab-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Funding overview

Funding rounds8 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adimab